104 related articles for article (PubMed ID: 16740694)
1. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness.
Zhang Y; Zhang B
Cancer Res; 2006 Jun; 66(11):5592-8. PubMed ID: 16740694
[TBL] [Abstract][Full Text] [Related]
2. Mutated D4-guanine diphosphate-dissociation inhibitor is found in human leukemic cells and promotes leukemic cell invasion.
Nakata Y; Kondoh K; Fukushima S; Hashiguchi A; Du W; Hayashi M; Fujimoto J; Hata J; Yamada T
Exp Hematol; 2008 Jan; 36(1):37-50. PubMed ID: 18037226
[TBL] [Abstract][Full Text] [Related]
3. Association of D4-GDI expression with breast cancer progression.
Rivera Rosado LA; Rodriguez-Canales J; Zhang B
Cancer Biomark; 2011-2012; 10(3-4):163-73. PubMed ID: 22674302
[TBL] [Abstract][Full Text] [Related]
4. Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling.
Zhang Y; Rivera Rosado LA; Moon SY; Zhang B
J Biol Chem; 2009 May; 284(19):12956-65. PubMed ID: 19269969
[TBL] [Abstract][Full Text] [Related]
5. Altered cellular immunity in transgenic mice with T cell-specific expression of human D4-guanine diphosphate-dissociation inhibitor (D4-GDI).
Kondoh K; Nakata Y; Yamaoka T; Itakura M; Hayashi M; Yamada K; Hata J; Yamada T
Int Immunol; 2008 Oct; 20(10):1299-311. PubMed ID: 18689726
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells.
Schunke D; Span P; Ronneburg H; Dittmer A; Vetter M; Holzhausen HJ; Kantelhardt E; Krenkel S; Müller V; Sweep FC; Thomssen C; Dittmer J
Cancer Res; 2007 Nov; 67(22):10694-702. PubMed ID: 18006811
[TBL] [Abstract][Full Text] [Related]
7. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis.
Zhang B; Zhang Y; Dagher MC; Shacter E
Cancer Res; 2005 Jul; 65(14):6054-62. PubMed ID: 16024605
[TBL] [Abstract][Full Text] [Related]
8. Cleavage and nuclear translocation of the caspase 3 substrate Rho GDP-dissociation inhibitor, D4-GDI, during apoptosis.
Krieser RJ; Eastman A
Cell Death Differ; 1999 May; 6(5):412-9. PubMed ID: 10381642
[TBL] [Abstract][Full Text] [Related]
9. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
Wu Y; McRoberts K; Berr SS; Frierson HF; Conaway M; Theodorescu D
Oncogene; 2007 Feb; 26(5):765-73. PubMed ID: 16878152
[TBL] [Abstract][Full Text] [Related]
10. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells.
Belguise K; Kersual N; Galtier F; Chalbos D
Oncogene; 2005 Feb; 24(8):1434-44. PubMed ID: 15608675
[TBL] [Abstract][Full Text] [Related]
11. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer.
Cho HJ; Baek KE; Park SM; Kim IK; Choi YL; Cho HJ; Nam IK; Hwang EM; Park JY; Han JY; Kang SS; Kim DC; Lee WS; Lee MN; Oh GT; Kim JW; Lee CW; Yoo J
Clin Cancer Res; 2009 Apr; 15(8):2612-9. PubMed ID: 19351766
[TBL] [Abstract][Full Text] [Related]
12. Reduced expression of Rho guanine nucleotide dissociation inhibitor-alpha modulates the cytotoxic effect of busulfan in HEK293 cells.
Reimer J; Bien S; Sonnemann J; Beck JF; Wieland T; Kroemer HK; Ritter CA
Anticancer Drugs; 2007 Mar; 18(3):333-40. PubMed ID: 17264767
[TBL] [Abstract][Full Text] [Related]
13. GDP dissociation inhibitor D4-GDI (Rho-GDI 2), but not the homologous rho-GDI 1, is cleaved by caspase-3 during drug-induced apoptosis.
Essmann F; Wieder T; Otto A; Müller EC; Dörken B; Daniel PT
Biochem J; 2000 Mar; 346 Pt 3(Pt 3):777-83. PubMed ID: 10698706
[TBL] [Abstract][Full Text] [Related]
14. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells.
Lindberg K; Ström A; Lock JG; Gustafsson JA; Haldosén LA; Helguero LA
J Cell Physiol; 2010 Jan; 222(1):156-67. PubMed ID: 19780039
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers.
Wu M; Wu ZF; Rosenthal DT; Rhee EM; Merajver SD
Cancer; 2010 Jun; 116(11 Suppl):2768-82. PubMed ID: 20503409
[TBL] [Abstract][Full Text] [Related]
16. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.
Cho HJ; Baek KE; Park SM; Kim IK; Nam IK; Choi YL; Park SH; Im MJ; Choi J; Ryu J; Kim JW; Lee CW; Kang SS; Yoo J
Cancer Lett; 2011 Dec; 311(1):48-56. PubMed ID: 21752536
[TBL] [Abstract][Full Text] [Related]
17. Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.
Ma L; Xu G; Sotnikova A; Szczepanowski M; Giefing M; Krause K; Krams M; Siebert R; Jin J; Klapper W
Br J Haematol; 2007 Oct; 139(2):217-23. PubMed ID: 17897297
[TBL] [Abstract][Full Text] [Related]
18. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.
Gildea JJ; Seraj MJ; Oxford G; Harding MA; Hampton GM; Moskaluk CA; Frierson HF; Conaway MR; Theodorescu D
Cancer Res; 2002 Nov; 62(22):6418-23. PubMed ID: 12438227
[TBL] [Abstract][Full Text] [Related]
19. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
Chen J; Miller EM; Gallo KA
Oncogene; 2010 Aug; 29(31):4399-411. PubMed ID: 20514022
[TBL] [Abstract][Full Text] [Related]
20. Fascin, an actin-bundling protein, promotes breast cancer progression in vitro.
Xing P; Li JG; Jin F; Zhao TT; Liu Q; Dong HT; Wei XL
Cell Biochem Funct; 2011 Jun; 29(4):303-10. PubMed ID: 21491467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
